Immorna (Hangzhou) Biotechnology Co., Ltd has announced the successful closure of Series A+ and A++ financing rounds, raising close to USD 100 million. The funding was led by Guodiao Innovation Private Equity Investment Fund Management (Hainan), Yuexiu Fund, GL Ventures, Zhenji Capital, C&D Emerging Industry Investment, TigerYeah Capital, and others, with additional support from existing investors Co-Win VC, China Growth Capital, and Zheshang Venture Capital. The proceeds will be directed towards clinical trials and pre-clinical development.
Company Overview and Technology
Immorna, an mRNA specialist established in 2019, has developed a comprehensive set of mRNA delivery systems, including polymers and nanoliposome particles. The company’s product pipelines cover a broad range of applications, such as cancer immunotherapy, infectious diseases, rare genetic diseases, and medical cosmetology. This diverse portfolio positions Immorna at the forefront of mRNA technology, offering innovative solutions across multiple therapeutic areas.
Clinical Development Milestones
Immorna has initiated four regulatory clinical trials targeting three indications in the US and China, demonstrating the company’s commitment to advancing its mRNA therapies through rigorous clinical testing. With multiple pipelines expected to enter the clinics this year, Immorna is poised to make significant strides in bringing its innovative treatments to market.
Strategic Implications
The successful Series A+ and A++ financing rounds underscore Immorna’s strong investor confidence and the potential of its mRNA platform. By securing substantial funding, Immorna can accelerate its clinical development programs, enhancing its ability to deliver effective mRNA-based therapies to patients in need. This funding will also support the expansion of Immorna’s research and development capabilities, further solidifying its position in the global mRNA landscape.-Fineline Info & Tech
